Zobrazit minimální záznam

Survival in Elderly Ovarian Cancer Remains Challenging in the Nordic Countries

dc.contributor.authorHemminki, Kari Jussi
dc.contributor.authorZitrický, František
dc.contributor.authorFörsti, Asta
dc.contributor.authorHemminki, Akseli
dc.date.accessioned2024-11-08T07:41:01Z
dc.date.available2024-11-08T07:41:01Z
dc.date.issued2024
dc.identifier.urihttps://hdl.handle.net/20.500.14178/2680
dc.description.abstractBACKGROUND: Despite treatment having improved through intensive surgical procedures and chemotherapy-and more recently, targeted therapies-ovarian cancer is the most fatal female cancer. As such, we wanted to analyze age-specific survival trends for ovarian cancer in Denmark, Finland, Norway and Sweden over the past 50 years, with a special aim of comparing survival development between the age groups. METHODS: We modelled survival data from the NORDCAN database for 1-, 5- and conditional 5/1-year relative (between years 1 and 5) survival for ovarian cancer from 1972 to 2021. RESULTS: Young patients had a 70% 5-year survival while the survival was only 30% for the oldest patients. Conditional survival showed that survival between years 1 and 5 did not improve for patients older than 60 years throughout the 50-year period, during which time the gaps between the youngest and the oldest patients widened. CONCLUSIONS: Improvement in 1-year survival was so large that it masked the modest development between years 1 and 5, resulting in a widening age disparity in 5-year survival. The current treatment practices, which appear increasingly effective for younger patients, have not helped remedy the large age differences in ovarian cancer survival. Early detection methods and therapeutic innovations are urgently needed, and aged patients need a special focus.en
dc.language.isoen
dc.relation.urlhttps://doi.org/10.3390/cancers16122198
dc.rightsCreative Commons Uveďte původ 4.0 Internationalcs
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.titleSurvival in Elderly Ovarian Cancer Remains Challenging in the Nordic Countriesen
dcterms.accessRightsopenAccess
dcterms.licensehttps://creativecommons.org/licenses/by/4.0/legalcode
dc.date.updated2024-11-08T07:41:01Z
dc.subject.keywordcarboplatin cancer controlen
dc.subject.keywordprognosisen
dc.subject.keywordrelative survivalen
dc.subject.keywordtreatmenten
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MSM//LX22NPO5102
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MSM//EH22_008/0004644
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/EU/FP8/856620
dc.date.embargoStartDate2024-11-08
dc.type.obd73
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.identifier.doi10.3390/cancers16122198
dc.identifier.utWos001254678700001
dc.identifier.eidScopus2-s2.0-85197194884
dc.identifier.obd649213
dc.identifier.pubmed38927904
dc.subject.rivPrimary30000::30200::30204
dcterms.isPartOf.nameCancers
dcterms.isPartOf.issn2072-6694
dcterms.isPartOf.journalYear2024
dcterms.isPartOf.journalVolume16
dcterms.isPartOf.journalIssue12
uk.faculty.primaryId111
uk.faculty.primaryNameLékařská fakulta v Plznics
uk.faculty.primaryNameFaculty of Medicine in Pilsenen
uk.department.primaryId100012968318
uk.department.primaryNameBiomedicínské centrumcs
uk.department.primaryNameBiomedical Centeren
dc.type.obdHierarchyCsČLÁNEK V ČASOPISU::článek v časopisu::původní článekcs
dc.type.obdHierarchyEnJOURNAL ARTICLE::journal article::original articleen
dc.type.obdHierarchyCode73::152::206en
uk.displayTitleSurvival in Elderly Ovarian Cancer Remains Challenging in the Nordic Countriesen


Soubory tohoto záznamu

Thumbnail

Tento záznam se objevuje v následujících kolekcích

Zobrazit minimální záznam